(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.82%) $83.16
(-1.16%) $1.619
(-0.35%) $2 339.10
(-0.15%) $27.50
(0.49%) $926.60
(-0.19%) $0.933
(-0.20%) $11.00
(-0.25%) $0.798
(0.00%) $92.17
2.32% HKD 17.62
Live Chart Being Loaded With Signals
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China...
Stats | |
---|---|
Dagens volum | 970 500 |
Gjennomsnittsvolum | 5.62M |
Markedsverdi | 104.48B |
EPS | HKD0 ( 2024-03-26 ) |
Last Dividend | HKD0.0707 ( 2023-09-15 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 31.46 |
ATR14 | HKD0.0390 (0.22%) |
Volum Korrelasjon
Hansoh Pharmaceutical Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Hansoh Pharmaceutical Korrelasjon - Valuta/Råvare
Hansoh Pharmaceutical Økonomi
Annual | 2023 |
Omsetning: | HKD10.10B |
Bruttogevinst: | HKD9.07B (89.78 %) |
EPS: | HKD0.520 |
FY | 2023 |
Omsetning: | HKD10.10B |
Bruttogevinst: | HKD9.07B (89.78 %) |
EPS: | HKD0.520 |
FY | 2022 |
Omsetning: | HKD9.38B |
Bruttogevinst: | HKD8.51B (90.73 %) |
EPS: | HKD0.440 |
FY | 2021 |
Omsetning: | HKD9.94B |
Bruttogevinst: | HKD9.07B (91.24 %) |
EPS: | HKD0.460 |
Financial Reports:
No articles found.
Hansoh Pharmaceutical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0.0500 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.0500 (N/A) |
HKD0.141 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.0771 | 2021-06-07 |
Last Dividend | HKD0.0707 | 2023-09-15 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 8 | -- |
Total Paid Out | HKD0.576 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.77 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.65 | |
Div. Directional Score | 8.95 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
2218.HK | Ex Dividend Junior | 2023-06-02 | Annually | 0 | 0.00% | |
1224.HK | No Dividend Player | 2023-05-24 | Annually | 0 | 0.00% | |
0303.HK | Ex Dividend Knight | 2023-07-21 | Semi-Annually | 0 | 0.00% | |
3989.HK | Ex Dividend Junior | 2023-07-07 | Sporadic | 0 | 0.00% | |
1795.HK | Ex Dividend Junior | 2023-06-30 | Annually | 0 | 0.00% | |
0830.HK | Ex Dividend Junior | 2023-06-13 | Annually | 0 | 0.00% | |
2380.HK | Ex Dividend Junior | 2023-06-12 | Annually | 0 | 0.00% | |
1361.HK | Ex Dividend Knight | 2023-08-28 | Annually | 0 | 0.00% | |
0423.HK | Ex Dividend Junior | 2023-08-10 | Semi-Annually | 0 | 0.00% | |
6808.HK | Ex Dividend Junior | 2023-08-22 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.324 | 1.500 | 3.51 | 5.27 | [0 - 0.5] |
returnOnAssetsTTM | 0.0992 | 1.200 | 6.69 | 8.03 | [0 - 0.3] |
returnOnEquityTTM | 0.131 | 1.500 | 9.65 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 4.21 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 4.02 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 3.27 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.130 | -1.500 | 7.84 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.174 | 2.00 | 9.94 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.160 | 2.00 | 9.92 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.166 | -1.500 | 9.34 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.898 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.265 | 1.000 | 6.70 | 6.70 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.267 | 1.000 | 9.63 | 9.63 | [0.2 - 2] |
assetTurnoverTTM | 0.306 | 0.800 | -1.295 | -1.036 | [0.5 - 2] |
Total Score | 11.25 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 32.05 | 1.000 | 6.86 | 0 | [1 - 100] |
returnOnEquityTTM | 0.131 | 2.50 | 9.78 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.160 | 2.00 | 9.95 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 1.201 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.174 | 2.00 | 9.94 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 4.50 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.113 | 1.000 | 9.66 | 0 | [0.1 - 0.5] |
Total Score | 6.65 |
Hansoh Pharmaceutical
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including central nervous system diseases, oncology, anti-infectives, and metabolic diseases. Its principal products include Mailingda, a drug for the treatment of chronic myelogenous leukemia; and Ameile, Hansoh Xinfu, Pulaile, Zefei, Xinwei, Xinmei, Xintai, Tanneng, Oulanning, Ameining, Zetan, Hengjie, Hengsen, Fulaimei, Fulaidi, and Ruibote drugs. The company serves pharmaceutical product distributors. It has a strategic collaboration with Scynexis, Inc. to develop and commercialize ibrexafungerp for treatment of vaginal yeast infections; and strategic collaboration with Keros to develop, manufacture, and commercialize KER-050 for treatment of cytopenias, anemia, and thrombocytopenia. The company also has a collaboration with Olix Pharmaceuticals for development of drug candidates for cardiovascular, metabolic, and other diseases associated with the liver; and strategic collaboration with Silence Therapeutics plc to develop siRNAs for three targets leveraging Silence's mRNAi GOLD platform. The company was founded in 1995 and is headquartered in Lianyungang, the People's Republic of China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.